Actively Recruiting
Evaluation of LTZ-232 Safety and Preliminary Antitumor Activity in Adults With Advanced or Metastatic Colorectal Cancer and Other Solid Tumors
Led by LTZ Therapeutics, Inc. · Updated on 2026-11-03
152
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating LTZ-232, an engineered anti-EPCAM bispecific antibody, in adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard therapies. This first-in-human, Phase 1, multi-center, open-label trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of LTZ-232. Participants receive LTZ-232 intravenously every two weeks for up to 24 months unless treatment discontinuation criteria are met. The study includes up to eight escalating dose level cohorts to identify safe dosing, followed by expansion cohorts to further evaluate safety and clinical activity at selected doses. Throughout the study, participants undergo regular monitoring to assess safety and tolerability, including tracking adverse events according to CTCAE v5.0. Researchers also evaluate treatment effects on tumor size using standardized criteria. The overall participation can last up to 24 months, during which detailed laboratory tests and clinical assessments are conducted to characterize the treatments impact.
CONDITIONS
Brief Title
This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
Research Team
S
Sherry Unabia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here